WaveMan · Company
XAGE · Longevity Health Holdings, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

XAGE Longevity Health (XAGE) Insider Trading, Ownership & Congress Trades

Consumer Goods · Soap, detergents, cleang preparations, perfumes, cosmetics · CIK 0001842939
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
0
13F, latest reported quarter
Revenue growth
+3701.4%
XBRL, annual
Net margin
-361.0%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$1.7M
four quarters, 2025-07-01 to 2026-06-30
History
FY Dec 2025$1.9M
FY Dec 2024$50.3K
FY Dec 2023n/a
FY Dec 2022n/a
Jun 2026$396.0K
Mar 2026$391.8K
Dec 2025$473.0K
Sep 2025$425.9K
Jun 2025$503.6K
Mar 2025$510.4K
Dec 2024$17.5K
Sep 2024$20.5K
At each fiscal year end
Single quarter
Net margin, TTM
-404.8%
net income over revenue, 2025-07-01 to 2026-06-30
History
FY Dec 2025-361.0%
FY Dec 2024n/a
FY Dec 2023n/a
FY Dec 2022n/a
Jun 2026-475.6%
Mar 2026-365.5%
Dec 2025-440.4%
Sep 2025-335.7%
Jun 2025-374.6%
Mar 2025-295.1%
Dec 2024n/a
Sep 2024n/a
At each fiscal year end
Single quarter
Free cash flow, TTM
n/a
capex not filed for the four quarters
History
FY Dec 2025n/a
FY Dec 2024n/a
FY Dec 2023n/a
FY Dec 2022n/a
Jun 2026n/a
Mar 2026n/a
Dec 2025-$306.4K
Sep 2025n/a
Jun 2025n/a
Mar 2025n/a
Dec 2024n/a
Sep 2024n/a
At each fiscal year end
Single quarter
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
History
FY Dec 2025n/a
FY Dec 2024n/a
FY Dec 20230.38x
FY Dec 2022n/a
Jun 2026n/a
Mar 2026n/a
Dec 2025n/a
Sep 2025n/a
Jun 2025n/a
Mar 2025n/a
Dec 2024n/a
Sep 2024n/a
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-0.26x
TTM operating cash flow over long-term debt only, 2023-09-30 (33 months older than the period end)
History
FY Dec 2025-0.36x
FY Dec 2024-0.42x
FY Dec 2023-0.89x
FY Dec 2022n/a
Jun 2026-0.26x
Mar 2026-0.33x
Dec 2025-0.36x
Sep 2025-0.41x
Jun 2025-0.35x
Mar 2025-0.38x
Dec 2024-0.42x
Sep 2024-0.70x
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
n/a
average equity is zero or negative
History
FY Dec 2025n/a
FY Dec 2024-103.5%
FY Dec 2023n/a
FY Dec 2022n/a
Jun 2026n/a
Mar 2026n/a
Dec 2025n/a
Sep 2025n/a
Jun 2025n/a
Mar 2025n/a
Dec 2024-103.5%
Sep 2024-74.7%
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-286.0%
TTM net income over average of 2025-06-30 and 2026-06-30
History
FY Dec 2025-359.6%
FY Dec 2024-31.7%
FY Dec 2023-47.0%
FY Dec 2022n/a
Jun 2026-286.0%
Mar 2026-274.4%
Dec 2025-359.6%
Sep 2025-199.8%
Jun 2025-164.2%
Mar 2025-180.8%
Dec 2024-31.7%
Sep 2024-14.9%
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
History
FY Dec 2025n/a
FY Dec 2024n/a
FY Dec 2023n/a
FY Dec 2022n/a
Jun 2026n/a
Mar 2026n/a
Dec 2025n/a
Sep 2025n/a
Jun 2025n/a
Mar 2025n/a
Dec 2024n/a
Sep 2024n/a
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
n/a
capital employed is zero or negative
History
FY Dec 2025n/a
FY Dec 2024-47.5%
FY Dec 2023-59.7%
FY Dec 2022n/a
Jun 2026n/a
Mar 2026n/a
Dec 2025n/a
Sep 2025n/a
Jun 2025n/a
Mar 2025n/a
Dec 2024-47.5%
Sep 2024-21.2%
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
History
FY Dec 2025n/a
FY Dec 2024n/a
FY Dec 2023n/a
FY Dec 2022n/a
Jun 2026n/a
Mar 2026n/a
Dec 2025n/a
Sep 2025n/a
Jun 2025n/a
Mar 2025n/a
Dec 2024n/a
Sep 2024n/a
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$9.6M
market value at close 2026-10-09 on 2026-08-13 shares, plus long-term debt only, 2023-09-30 (33 months older than the period end), minus cash 2026-06-30
History
FY Dec 2025$9.2M
FY Dec 2024$184.2M
FY Dec 2023$2.6B
FY Dec 2022n/a
Jun 2026$10.0M
Mar 2026$9.8M
Dec 2025$9.2M
Sep 2025$10.5M
Jun 2025$11.7M
Mar 2025$122.2M
Dec 2024$184.2M
Sep 2024$260.3M
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
n/a
capex not filed for the four quarters
History
FY Dec 2025n/a
FY Dec 2024n/a
FY Dec 2023n/a
FY Dec 2022n/a
Jun 2026n/a
Mar 2026n/a
Dec 2025n/a
Sep 2025n/a
Jun 2025n/a
Mar 2025n/a
Dec 2024n/a
Sep 2024n/a
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
History
FY Dec 2025n/a
FY Dec 2024n/a
FY Dec 2023n/a
FY Dec 2022n/a
Jun 2026n/a
Mar 2026n/a
Dec 2025n/a
Sep 2025n/a
Jun 2025n/a
Mar 2025n/a
Dec 2024n/a
Sep 2024n/a
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-09. Hover a figure to see how it was computed.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.

XAGE Stock Sonar score 3/7 axes

Find similar shapesCompare

XAGE ranks highest on growth (99th percentile) and risk and compliance (88th), and lowest on financial health (15th), among Consumer Goods peers.

Financial health
15
Inputs
  • Debt to equityequity is zero or negative, the ratio has no meaning
  • Cash flow to debt-0.26x · 15 pct, sector of 97
Growth
99
Inputs
  • Revenue growth, YoY+3701% · 99 pct, sector of 146
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Risk and compliance
88
Inputs
  • Short interest, % of float+0.2% · 89 pct, sector of 159
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+5.0% · 88 pct, sector of 111
4 not measured: Profitability, Insider conviction, Institutional and government, US patents
  • Profitability needs 2 of 4 inputs, 1 present: average equity is zero or negative; capital employed is zero or negative; pre-tax loss, no effective tax rate to apply
  • Insider conviction needs 1 of 2 inputs, 0 present: no insider trades in 180 days; no open-market insider trades in 180 days
  • Institutional and government needs 1 of 4 inputs, 0 present: fewer than five funds report holding it; no Congress trades in 365 days; no federal contracts in 180 days; no lobbying filings in the last four quarters
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

3 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

What the filings say about XAGE

The latest 5% ownership filing is a 13D by Ajjarapu J. Ram, filed 2026-04-08, for 27.9% of the class. Each figure is counted from SEC and House filings as of 2026-10-12, dated the day the filing was made public.

Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no Congress trades reported
Funds
under five funds report holding it
Revenue
+3701.4% year over year
more than 99% of Consumer Goods
Margin
-361.0% net margin
below 96% of Consumer Goods
Buybacks
no share repurchases reported
Short interest
0.2% of the float short (float per yahoo 2026-10-09) · 1.0 days to cover · settled 2026-09-30
below 84% of Consumer Goods
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch XAGE

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-81.6%12M
-82%-46%-10%+26%2025-102025-122026-022026-042026-062026-082026-10 2026-03-16 · Ajjarapu J. Ram bought $200.0K2026-04-08 · Ajjarapu J. Ram filed a 5%+ stake (27.9%)2026-04-08 · International Capital Partners LLC filed a 5%+ stake (27.9%)
Insider buy13D/G stake
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
Each figure here is a federal filing, dated the day it went public, so you can test what was knowable then.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
ELFFNKOPTONPGVTSIECLATERELMHKCHDCALLEVI

Longevity Health insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for Longevity Health Holdings, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-12.

Insider
Filed
Shares
Value
Ajjarapu J. Ram
Chief Executive Officer
BUY
2026-03-16
689,656
$200.0K
Context
  • First open-market trade here by this insider on our record.
  • The trade is 100.0% of the 689,656 shares held after it.
  • No other insider bought within 30 days.
Insider activity: Chief Executive Officer Ajjarapu J. Ram bought about $200.0K of XAGE on the open market on Mar 16, 2026, the largest insider purchase at the company on our record.
1 transaction on record · a thin record, read with care
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to use the screener and CSV export. We store only your email; there is no password.

Who owns XAGE: institutional holders (13F)

13F holdings, latest reported quarter
SEC 13F
No reported 13F holders

No fund above the reporting threshold listed this stock last quarter. That is a fact, not missing data.

Congress trades in XAGE

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

13D: intends to influence · 13G: passive
Ajjarapu J. Ram
Activist 13D · 2026-04-08
27.9%
International Capital Partners LLC
Activist 13D · 2026-04-08
27.9%

XAGE planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$1.9M$50.3K$0n/a
Gross profit$1.1M$44.0K$0n/a
Operating income$-7.1M$-5.0M$-5.9M$-5.5M
Net income$-6.9M$-10.4M$-15.4M$-9.1M
EPS (diluted)-4.83-14.56-1.46-5.47
Operating cash flow$-3.3M$-3.9M$-8.3M$-3.4M
Cash$706.7K$157.1K$2.9M$128.1K
Buybacksn/an/a$0$2.3K
SEC XBRL, fiscal years, as known on 2026-10-12

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies